New Real-World Data Show High Rate of Patient Adherence to TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announces findings of a real-world adherence analysis of TEPEZZA (teprotumumab-trbw) for the treatment of TED at AAO 2021.